Literature DB >> 23945143

Cognitive deficits in Korean women treated with chemotherapy for breast cancer.

Mi Sook Jung1, Bernadine Cimprich.   

Abstract

BACKGROUND: Cognitive deficits have been reported as detrimental side effects in chemotherapy-treated breast cancer patients and survivors. Korean women treated for breast cancer may experience unrecognized cognitive deficits related to their treatment. However, no research has examined cognitive test performance in chemotherapy-treated Korean breast cancer survivors.
OBJECTIVE: The objectives of this study were 2-fold: (1) to examine differences in occurrence and severity of cognitive deficits in Korean women treated with adjuvant chemotherapy for breast cancer as compared with a control group of women without breast cancer and (2) to examine the relationship of selected demographic and cultural factors with cognitive test performance.
METHODS: Sixty-four Korean women, 32 women treated for localized breast cancer and 32 healthy controls, were enrolled. Breast cancer participants were assessed with established cognitive measures within 4 months after chemotherapy, and healthy controls, within 6 months after negative screening mammography.
RESULTS: The breast cancer group showed a significantly higher occurrence and greater severity of cognitive deficits than controls did. Importantly, older age, less education, greater collectivist tendency, and greater childrearing burden were reliably associated with poorer attention and working memory test performance.
CONCLUSIONS: Cognitive deficits were found in chemotherapy-treated Korean women with moderate to large effect sizes compared with controls. Cultural characteristics contributed to worse cognitive performance. IMPLICATIONS FOR PRACTICE: Healthcare providers should recognize that Korean women may be highly vulnerable to cognitive deficits. Cultural factors also need to be considered when assessing cognitive function and designing therapeutic interventions to counteract negative cognitive outcomes.

Entities:  

Mesh:

Year:  2014        PMID: 23945143     DOI: 10.1097/NCC.0b013e3182980383

Source DB:  PubMed          Journal:  Cancer Nurs        ISSN: 0162-220X            Impact factor:   2.592


  8 in total

1.  Post-treatment cognitive dysfunction in women treated with thyroidectomy for papillary thyroid carcinoma.

Authors:  Mi Sook Jung; Moira Visovatti
Journal:  Support Care Cancer       Date:  2016-11-11       Impact factor: 3.603

2.  Assessing Physical and Cognitive Function in Individuals With Head and Neck Cancer: A Feasibility Study.

Authors:  Moira A Visovatti; Mi Sook Jung; Heidi Mason; Mary Beth DeRubeis; Francis P Worden; Debra L Barton
Journal:  Cancer Nurs       Date:  2022-01-12       Impact factor: 2.760

3.  Assessment of Cognitive Impairment and Complaints in Individuals With Colorectal Cancer.

Authors:  Moira A Visovatti; Patricia A Reuter-Lorenz; Alfred E Chang; Laurel Northouse; Bernadine Cimprich
Journal:  Oncol Nurs Forum       Date:  2016-03       Impact factor: 1.803

Review 4.  Four decades of chemotherapy-induced cognitive dysfunction: comprehensive review of clinical, animal and in vitro studies, and insights of key initiating events.

Authors:  Ana Dias-Carvalho; Mariana Ferreira; Rita Ferreira; Maria de Lourdes Bastos; Susana Isabel Sá; João Paulo Capela; Félix Carvalho; Vera Marisa Costa
Journal:  Arch Toxicol       Date:  2021-11-02       Impact factor: 5.153

5.  Quality of Life of Women After a First Diagnosis of Breast Cancer Using a Self-Management Support mHealth App in Taiwan: Randomized Controlled Trial.

Authors:  I-Ching Hou; Hsin-Yi Lin; Shan-Hsiang Shen; King-Jen Chang; Hao-Chih Tai; Ay-Jen Tsai; Patricia C Dykes
Journal:  JMIR Mhealth Uhealth       Date:  2020-03-04       Impact factor: 4.773

6.  Clinical impact of melatonin on breast cancer patients undergoing chemotherapy; effects on cognition, sleep and depressive symptoms: A randomized, double-blind, placebo-controlled trial.

Authors:  Ana Claudia Souza Palmer; Maxciel Zortea; Andressa Souza; Vinicius Santos; Jorge Villanova Biazús; Iraci L S Torres; Felipe Fregni; Wolnei Caumo
Journal:  PLoS One       Date:  2020-04-17       Impact factor: 3.240

7.  Prevalence of cognitive impairment following chemotherapy treatment for breast cancer: a systematic review and meta-analysis.

Authors:  Alexandra L Whittaker; Rebecca P George; Lucy O'Malley
Journal:  Sci Rep       Date:  2022-02-08       Impact factor: 4.379

Review 8.  Cognitive Effects of Cancer and Cancer Treatments.

Authors:  Tim A Ahles; James C Root
Journal:  Annu Rev Clin Psychol       Date:  2018-01-18       Impact factor: 22.098

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.